FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2585997529> ?p ?o ?g. }

• W2585997529 endingPage "2014" @default.
• W2585997529 startingPage "2014" @default.
• W2585997529 abstract "Abstract The use of CB for stem cell transplantation is increasing. A major disadvantage of CB is delayed and failed engraftment when compared to marrow or blood transplantation. Double CBT and ex-vivo expansion are both strategies being investigated in order to improve hematopoietic reconstitution. We compared these approaches with the aim of improving the clinical outcomes of CBT patients. 48 patients were randomized to receive either two unmanipulated (UNM) CB units (N=24) or one UNM unit and one unit from which all the cells were EXP ex-vivo (N=24). Most CB units were HLA 4/6 matches. Diagnoses were AML (N=16), ALL(N=13), NHL(N= 5), HD(N=7), CML (N=5), and CLL(N=2). Patients (Table 1) were heavily pre-treated, with a median of 3 (1–8) prior regimens including autotransplants in 18%. Preparative regimens included ATG and either fludara plus dose-adjusted busulfan(N=13; myeloid diseases), or melphalan and thiotepa (N=21; lymphoid malignancies/HD); patients not eligible for high-dose therapy received non-myeloablative fludara plus cyclophosphamide and 200 GyTBI (=11) or melphalan(n=3). GVHD prophylaxis was tacrolimus plus either 3 doses of 5 mg/m2 methotrexate or MMF (table 1). Ex-vivo expansion: the smallest unit was CD133-selected using the CliniMACS device (day -14). The T cell-containing CD133-negative fraction was frozen. The CD133+ fraction was cultured for 14 days in media containing SCF, G-CSF and TPO. On day 0, the 2nd UNM unit was infused, followed by the CD133-negative and the EXP fractions. Results. Infused median total nucleated cells (TNC)×108/Kg was 0.36 and 0.36, and median CD34×106/Kg was 0.16 and 0.13, respectively for EXP and UNM pts. Median TNC fold-expansion was 26 (0.44–275) and for CD34+ cells, 2.2 (0–18). There was a nonsignificant trend to more rapid engraftment in patients receiving EXP cells. Patients with &gt;50-fold versus &lt;50-fold TNC expansion engrafted in a median of 19 days(11–21) versus 23 (16–31), and achieved platelets&gt;20K/ul at a median of 29 days(17–44) versus 42(29–56). 25 patients are alive [median follow up is 11.1 mo (2–33.6)]. 100-day and 1-year non-relapse mortality rates are 10% and 22%, respectively (table 2). Chimerism showed that 1 CB unit dominated in all patients. Among 19 evaluable EXP patients, in 63% the UNM unit provided 100% of the hematopoiesis from day +30; the EXP unit was predominant in 3 cases (for 12, 2 and 2 mo.) and present but not predominant in 4 (5–25%, for 12, 7, 3 and 3 mo). Conclusion: EXP CBT was safe. The range of fold-expansion was highly variable. Accrual continues focusing on strategies which improve CB expansion. Outcomes Expanded Unmanipulated P C.Incid.: cumulative incidence Time to ANC500 (median/95%CI) 20 days (15, 31) 23.5 (21, 34) 0.4 Proportion engrafting ANC500 82% (n=19) 79% (n=19) 1 Time to PLT20K (median/95%CI) 41 (32, NA) 54 (40, NA) 0.4 Proportion engrafting PLT 67% (n=16) 58% (n=14) 0.38 1-year survival 60% 40% 0.45 aGVHD gd II–IV/ III–IV 32% / 5% 41% / 9% NS C.Incid. cGVHD 47% (28–78) 31% (15–65) NS Expanded Unmanipulated P Complete remission at UCBT 42% 67% 0.15 Median weight 82 (20-113) 76 (51-144) 0.6 Median age 40.4 (4-66) 38.1 (9-65) 0.8 Ablative preparative regimen 67% 75% 0.8 GVHD prophylaxis with methotrexate 48% 48% NS" @default.
• W2585997529 created "2017-02-10" @default.
• W2585997529 creator A5002347804 @default.
• W2585997529 creator A5004417292 @default.
• W2585997529 creator A5007081796 @default.
• W2585997529 creator A5016928938 @default.
• W2585997529 creator A5017745708 @default.
• W2585997529 creator A5021095942 @default.
• W2585997529 creator A5033381380 @default.
• W2585997529 creator A5033737136 @default.
• W2585997529 creator A5034104852 @default.
• W2585997529 creator A5034264716 @default.
• W2585997529 creator A5040975741 @default.
• W2585997529 creator A5048913229 @default.
• W2585997529 creator A5049701586 @default.
• W2585997529 creator A5050962913 @default.
• W2585997529 creator A5055885795 @default.
• W2585997529 creator A5057435563 @default.
• W2585997529 creator A5057832944 @default.
• W2585997529 creator A5060637522 @default.
• W2585997529 creator A5070096873 @default.
• W2585997529 creator A5071526808 @default.
• W2585997529 creator A5081936426 @default.
• W2585997529 creator A5087389826 @default.
• W2585997529 creator A5088821817 @default.
• W2585997529 date "2007-11-16" @default.
• W2585997529 modified "2023-09-27" @default.
• W2585997529 title "Randomized Study of Double Cord Blood Transplantation (CBT) with Versus without Ex-Vivo Expansion (EXP)." @default.
• W2585997529 doi "https://doi.org/10.1182/blood.v110.11.2014.2014" @default.
• W2585997529 hasPublicationYear "2007" @default.
• W2585997529 type Work @default.
• W2585997529 sameAs 2585997529 @default.
• W2585997529 citedByCount "4" @default.
• W2585997529 countsByYear W25859975292012 @default.
• W2585997529 countsByYear W25859975292014 @default.
• W2585997529 crossrefType "journal-article" @default.
• W2585997529 hasAuthorship W2585997529A5002347804 @default.
• W2585997529 hasAuthorship W2585997529A5004417292 @default.
• W2585997529 hasAuthorship W2585997529A5007081796 @default.
• W2585997529 hasAuthorship W2585997529A5016928938 @default.
• W2585997529 hasAuthorship W2585997529A5017745708 @default.
• W2585997529 hasAuthorship W2585997529A5021095942 @default.
• W2585997529 hasAuthorship W2585997529A5033381380 @default.
• W2585997529 hasAuthorship W2585997529A5033737136 @default.
• W2585997529 hasAuthorship W2585997529A5034104852 @default.
• W2585997529 hasAuthorship W2585997529A5034264716 @default.
• W2585997529 hasAuthorship W2585997529A5040975741 @default.
• W2585997529 hasAuthorship W2585997529A5048913229 @default.
• W2585997529 hasAuthorship W2585997529A5049701586 @default.
• W2585997529 hasAuthorship W2585997529A5050962913 @default.
• W2585997529 hasAuthorship W2585997529A5055885795 @default.
• W2585997529 hasAuthorship W2585997529A5057435563 @default.
• W2585997529 hasAuthorship W2585997529A5057832944 @default.
• W2585997529 hasAuthorship W2585997529A5060637522 @default.
• W2585997529 hasAuthorship W2585997529A5070096873 @default.
• W2585997529 hasAuthorship W2585997529A5071526808 @default.
• W2585997529 hasAuthorship W2585997529A5081936426 @default.
• W2585997529 hasAuthorship W2585997529A5087389826 @default.
• W2585997529 hasAuthorship W2585997529A5088821817 @default.
• W2585997529 hasConcept C126322002 @default.
• W2585997529 hasConcept C126894567 @default.
• W2585997529 hasConcept C143998085 @default.
• W2585997529 hasConcept C150903083 @default.
• W2585997529 hasConcept C207001950 @default.
• W2585997529 hasConcept C26291073 @default.
• W2585997529 hasConcept C2776364478 @default.
• W2585997529 hasConcept C2776694085 @default.
• W2585997529 hasConcept C2776755627 @default.
• W2585997529 hasConcept C2777408962 @default.
• W2585997529 hasConcept C2778684742 @default.
• W2585997529 hasConcept C2779263901 @default.
• W2585997529 hasConcept C2779968505 @default.
• W2585997529 hasConcept C2780611847 @default.
• W2585997529 hasConcept C2911091166 @default.
• W2585997529 hasConcept C71924100 @default.
• W2585997529 hasConcept C86803240 @default.
• W2585997529 hasConcept C90924648 @default.
• W2585997529 hasConceptScore W2585997529C126322002 @default.
• W2585997529 hasConceptScore W2585997529C126894567 @default.
• W2585997529 hasConceptScore W2585997529C143998085 @default.
• W2585997529 hasConceptScore W2585997529C150903083 @default.
• W2585997529 hasConceptScore W2585997529C207001950 @default.
• W2585997529 hasConceptScore W2585997529C26291073 @default.
• W2585997529 hasConceptScore W2585997529C2776364478 @default.
• W2585997529 hasConceptScore W2585997529C2776694085 @default.
• W2585997529 hasConceptScore W2585997529C2776755627 @default.
• W2585997529 hasConceptScore W2585997529C2777408962 @default.
• W2585997529 hasConceptScore W2585997529C2778684742 @default.
• W2585997529 hasConceptScore W2585997529C2779263901 @default.
• W2585997529 hasConceptScore W2585997529C2779968505 @default.
• W2585997529 hasConceptScore W2585997529C2780611847 @default.
• W2585997529 hasConceptScore W2585997529C2911091166 @default.
• W2585997529 hasConceptScore W2585997529C71924100 @default.
• W2585997529 hasConceptScore W2585997529C86803240 @default.
• W2585997529 hasConceptScore W2585997529C90924648 @default.
• W2585997529 hasIssue "11" @default.
• W2585997529 hasLocation W25859975291 @default.
• W2585997529 hasOpenAccess W2585997529 @default.

• next